Issue 26
Why Biopharma Can’t Survive Without CDMOs in 2025
Why not sign up for our future email newsletters? Sign up here.
Included in this issue:
LEAD STORY
Outsource or Die? How CDMOs Will Shape Pharma in 2025 and Beyond
Overall, 2024 was a good year to be working in the CDMO industry, but will the outlook stay positive for 2025?
Read more here.
FEATURED STORIES
Lonza Drops CHI Business to Focus on CDMO Services
Read more here.
OneSource Expands GLP-1 Drug-Device Capacity as Demand Soars
Read more here.
SK pharmteco Unifies Global CDMO Brands to Streamline Drug Development Services
Read more here.
BIOSECURE Act Excluded from U.S. Defense Bill, Boosting Chinese Biotech Firms
Read more here.
Boryung Corp. and Lotus Pharmaceutical Forge CDMO Partnership for Anticancer Drug Production
Read more here.
Novo Holdings Receives EU Approval for Catalent Acquisition
Read more here.
Agenus Pivots to CDMO Services Amid Regulatory Setbacks
Read more here.
National Resilience Confirms Layoffs Amid Expansion and Leadership Change
Read more here.
Adragos Pharma Expands Global Footprint with Swiss Acquisition
Read more here.
Samabriva Expands Biomanufacturing Capabilities with New Belgian Facility
Read more here.
SCHOTT Pharma Announces Innovative Cartridge Nesting for Efficiency and Sustainability
Read more here.
